237
Views
25
CrossRef citations to date
0
Altmetric
Reviews

Immune monitoring of pancreatic islet graft: towards a better understanding, detection and treatment of harmful events

, , &
Pages 55-66 | Published online: 12 Nov 2010

Bibliography

  • Shapiro AM, Lakey JR, Ryan EA, Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-8
  • Toso C, Baertschiger R, Morel P, Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. Am J Transplant 2006;6:1049-58
  • Ryan EA, Paty BW, Senior PA, Five-year follow-up after clinical islet transplantation. Diabetes 2005;54:2060-9
  • Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol 2005;77:587-97
  • Roep BO, Stobbe I, Duinkerken G, Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999;48:484-90
  • Monti P, Scirpoli M, Maffi P, Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 2008;118:1806-14
  • Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007;117:2553-61
  • Campbell PM, Salam A, Ryan EA, Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant 2007;7:1242-8
  • Shapiro AMJ, Koh A, Salam A, Impact of different induction therapies on long term durability of insulin independence after clinical islet transplantation. Am J Transplant 2008;8(Suppl 2):234
  • Shapiro AMJ, Koh A, Kin T, Outcomes following alemtuzumab induction in clinical islet transplantation. Am J Transplant 2008;8(Suppl 2):235
  • Posselt A, Szot G, Frassetto L, Islet Allograft survival in type 1 diabetics using a calcineurin-free protocol based on efalizumab and sirolimus. Am J Transplant 2008;8(Suppl 2):235
  • Bellin MD, Kandaswamy R, Parkey J, Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008;8:2463-70
  • Jaeger C, Brendel MD, Hering BJ, IA-2 antibodies are only positive in association with GAD 65 and islet cell antibodies in islet transplanted insulin-dependent diabetes mellitus patients. Transplant Proc 1998;30:659-60
  • Bosi E, Braghi S, Maffi P, Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001;50:2464-71
  • Pinkse GGM, Tysma OHM, Bergen CAM, Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci USA 2005;102:18425-30
  • Toso C, Edgar R, Pawlick R, Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transpl Int 2009;22:182-91
  • Eriksson O, Eich T, Sundin A, Positron emission tomography in clinical islet transplantation. Am J Transplant 2009;9:2816-24
  • Biarnes M, Montolio M, Nacher V, Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 2002;51:66-72
  • Kaddis JS, Danobeitia JS, Niland JC, Multicenter analysis of novel and established variables associated with successful human islet isolation outcomes. Am J Transplant 2010;10:646-56
  • Toso C, Oberholzer J, Ris F, Factors affecting human islet of Langerhans isolation yields. Transplant Proc 2002;34:826-7
  • Lakey JRT, Kneteman NM, Rajotte RV, Effect of core pancreas temperature during cadaveric procurement on human islet isolation and functional viability. Transplantation 2002;73:1106-10
  • Baertschiger RM, Berney T, Morel P. Organ preservation in pancreas and islet transplantation. Curr Opin Organ Transplant 2008;13:59-66
  • Noguchi H, Naziruddin B, Onaca N, Comparison of modified Celsior solution and M-Kyoto solution for pancreas preservation in human islet isolation. Cell Transplant 2010;19:751-8
  • Hammar E, Parnaud G, Bosco D, Extracellular matrix protects pancreatic beta-cells against apoptosis: role of short- and long-term signaling pathways. Diabetes 2004;53:2034-41
  • Parnaud G, Hammar E, Rouiller DG, Blockade of beta 1 integrin-laminin-5 interaction affects spreading and insulin secretion of rat beta-cells attached on extracellular matrix. Diabetes 2006;55:1413-20
  • Johansson U, Olsson A, Gabrielsson S, Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. Biochem Biophys Res Commun 2003;308:474-9
  • Lund T, Mangsbo SM, Scholz H, Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro. Exp Clin Endocrinol Diabetes 2010;118:237-44
  • Johansson H, Lukinius A, Moberg L, Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005;54:1755-62
  • Moberg L, Johansson H, Lukinius A, Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002;360:2039-45
  • Johansson H, Goto M, Dufrane D, Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation. Am J Transplant 2006;6:305-12
  • Merani S, Toso C, Emamaullee J, Shapiro AMJ. Optimal implantation site for pancreatic islet transplantation. Br J Surg 2008;95:1449-61
  • Moberg L, Korsgren O, Nilsson B. Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood. Clin Exp Immunol 2005;142:125-31
  • Moberg L, Olsson A, Berne C, Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation. Transplantation 2003;76:1285-8
  • Lund T, Fosby B, Korsgren O, Glucocorticoids reduce pro-inflammatory cytokines and tissue factor in vitro and improve function of transplanted human islets in vivo. Transpl Int 2008;2:669-78
  • Piemonti L, Leone BE, Nano R, Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 2002;51:55-65
  • Lai Y, Chen C, Linn T. Innate immunity and heat shock response in islet transplantation. Clin Exp Immunol 2009;157:1-8
  • Bottino R, Balamurugan AN, Tse H, Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes 2004;53:2559-68
  • Toso C, Serre-Beinier V, Emamaullee J, The role of macrophage migration inhibitory factor in mouse islet transplantation. Transplantation 2008;86:1361-9
  • Davalli AM, Scaglia L, Zangen DH, Vulnerability of islets in the immediate posttransplantation period. Dynamic changes in structure and function. Diabetes 1996;45:1161-7
  • Montolio M, Biarnes M, Tellez N, Interleukin-1beta and inducible form of nitric oxide synthase expression in early syngeneic islet transplantation. J Endocrinol 2007;192:169-77
  • Andres A, Toso C, Morel P, Macrophage depletion prolongs discordant but not concordant islet xenograft survival. Transplantation 2005;79:543-9
  • Bottino R, Fernandez LA, Ricordi C, Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation. Diabetes 1998;47:316-23
  • Toso C, Pawlick R, Lacotte S, Detecting rejection after mouse islet transplantation utilizing islet protein-stimulated ELISPOT. Cell Transplantation (In press)
  • Riethmuller S, Ferrari-Lacraz S, Muller MK, Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010;90:160-7
  • Mohanakumar T, Narayanan K, Desai N, A significant role for histocompatibility in human islet transplantation. Transplantation 2006;82:180-7
  • Ferrari-Lacraz S, Berney T, Morel P, Low risk of anti-human leukocyte antigen antibody sensitization after combined kidney and islet transplantation. Transplantation 2008;86:357-9
  • Campbell PM, Senior PA, Salam A, High risk of sensitization after failed islet transplantation. Am J Transplant 2007;7:2311-17
  • Cardani R, Pileggi A, Ricordi C, Allosensitization of islet allograft recipients. Transplantation 2007;84:1413-27
  • Olack BJ, Swanson CJ, Flavin KS, Sensitization to HLA antigens in islet recipients with failing transplants. Transplant Proc 1997;29:2268-9
  • Lobo PI, Spencer C, Simmons WD, Development of anti-human leukocyte antigen class 1 antibodies following allogeneic islet cell transplantation. Transplant Proc 2005;37:3438-40
  • Rickels MR, Kamoun M, Kearns J, Evidence for allograft rejection in an islet transplant recipient and effect on beta-cell secretory capacity. J Clin Endocrinol Metab 2007;92:2410-14
  • Kessler L, Parissiadis A, Bayle F, Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. Am J Transplant 2009;9:1961-6
  • Tuomilehto J, Zimmet P, Mackay IR, Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet 1994;343:1383-5
  • Verge CF, Gianani R, Kawasaki E, Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996;9:379-83
  • Hilbrands R, Huurman VAL, Gillard P, Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 2009;58:2267-76
  • Jaeger C, Hering BJ, Hatziagelaki E, Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression. J Mol Med 1999;77:45-8
  • Keymeulen B, Ling Z, Gorus FK, Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia 1998;41:452-9
  • Hering BJ, Kandaswamy R, Ansite JD, Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005;293:830-5
  • Martin S, Wolf-Eichbaum D, Duinkerken G, Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001;345:1036-40
  • van Kampen CA, van de Linde P, Duinkerken G, Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients. Transplantation 2005;80:118-26
  • Huurman VAL, Hilbrands R, Pinkse GGM, Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 2008;3:e2435
  • Huurman VAL, Velthuis JHL, Hilbrands R, Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am J Transplant 2009;9:382-8
  • Stobbe I, Duinkerken G, van Rood JJ, Tolerance to kidney allograft transplanted into type I diabetic patients persists after in vivo challenge with pancreatic islet allografts that express repeated mismatches. Diabetologia 1999;42:1379-80
  • Roelen DL, Huurman VAL, Hilbrands R, Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clin Exp Immunol 2009;156:141-8
  • Roelen DL, van Bree FP, Schanz U, Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. Transplantation 1993;56:190-5
  • Velthuis JH, Unger WW, Abreu JRF, Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010;59:1721-30
  • Vendrame F, Pileggi A, Laughlin E, Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010;59:947-57
  • Kowalski RJ, Post DR, Mannon RB, Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006;82:663-8
  • Cabrera R, Ararat M, Soldevila-Pico C, Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl 2009;15:216-22
  • Husain S, Raza K, Pilewski JM, Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation 2009;87:1852-7
  • Han D, Xu X, Baidal D, Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. Diabetes 2004;53:2281-90
  • Ritz-Laser B, Oberholzer J, Toso C, Molecular detection of circulating beta-cells after islet transplantation. Diabetes 2002;51:557-61
  • Berney T, Mamin A, James Shapiro AM, Detection of insulin mRNA in the peripheral blood after human islet transplantion predicts deterioration of metabolic control. Am J Transplant 2006;6:1704-11
  • Gagne K, Brouard S, Giral M, Highly altered V beta repertoire of T cells infiltrating long-term rejected kidney allografts. J Immunol 2000;164:1553-63
  • Brouard S, Mansfield E, Braud C, Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007;104:15448-53
  • Gunther OP, Balshaw RF, Scherer A, Functional genomic analysis of peripheral blood during early acute renal allograft rejection. Transplantation 2009;88:942-51
  • Pelzl S, Opelz G, Daniel V, Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003;75:421-3
  • Langan LL, Park LP, Hughes TL, Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007;7:847-56
  • Saini D, Ramachandran S, Nataraju A, Activated effector and memory T cells contribute to circulating sCD30: potential marker for islet allograft rejection. Am J Transplant 2008;8:1798-808
  • Hire K, Hering B, Bansal-Pakala P. Relative reductions in soluble CD30 levels post-transplant predict acute graft function in islet allograft recipients receiving three different immunosuppression protocols. Transpl Immunol 2010;23:209-14
  • Kurata Y, Kato M, Kuzuya T, Pretransplant pharmacodynamic analysis of immunosuppressive agents using CFSE-based T-cell proliferation assay. Clin Pharmacol Ther 2009;86:285-9
  • Friedl P, den Boer AT, Gunzer M. Tuning immune responses: diversity and adaptation of the immunological synapse. Nat Rev Immunol 2005;5:532-45
  • Toso C, Shapiro AMJ, Bowker S, Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome. Transplantation 2007;84:664-6
  • Benhamou PY, Milliat-Guittard L, Wojtusciszyn A, Quality of life after islet transplantation: data from the GRAGIL 1 and 2 trials. Diabet Med 2009;26:617-21
  • Andree H, Nickel P, Nasiadko C, Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 2006;17:573-80
  • Nickel P, Presber F, Bold G, Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004;78:1640-6
  • Toso C, Zaidi H, Morel P, Positron-emission tomography imaging of early events after transplantation of islets of Langerhans. Transplantation 2005;79:353-5
  • Toso C, Vallee J, Morel P, Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. Am J Transplant 2008;8:701-6
  • Eich T, Eriksson O, Lundgren T. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Engl J Med 2007;356:2754-5
  • Toso C, Isse K, Demetris A, Histologic graft assessment after clinical islet transplantation. Transplantation 2009;88:1286-93
  • Open-label investigation of the safety and effectiveness of DIABECELL(R) in patients with type i diabetes mellitus. Bethesda MD: ClinicalTrials.gov, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00940173?term=DIABECELL&rank=1 [Last accessed 1 November 2010]
  • Safety and efficacy study of encapsulated human islets allotransplantation to treat type 1 diabetes. Bethesda MD: ClinicalTrials.gov, 210. Available from: http://clinicaltrials.gov/ct2/show/NCT00790257?term=islet+encapsulation&rank=1 [Last accessed 1 November 2010]
  • Veriter S, Mergen J, Goebbels R, In vivo selection of biocompatible alginates for islet encapsulation and subcutaneous transplantation. Tissue Eng Part A 2010;16:1503-13
  • De Carlo E, Baiguera S, Conconi MT, Pancreatic acellular matrix supports islet survival and function in a synthetic tubular device: in vitro and in vivo studies. Int J Mol Med 2010;25:195-202
  • Krishnamurthy M, Wang R. Integrins and extracellular matrices in pancreatic tissue engineering. Front Biosci (Schol Ed) 2009;1:477-91
  • Augustine JJ, Siu DS, Clemente MJ, Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005;5:1971-5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.